The FDA’s ongoing review of several peptides continues to draw national attention following a closely watched vote by the Pharmacy Compounding Advisory Committee (PCAC). In a recent NPR article, the publication examines the growing interest in peptide therapies, the differing perspectives between FDA scientists and proponents of broader access, and what the committee’s recommendations could mean for the future of compounded peptides. While the committee voted to recommend allowing six peptides to move forward in the regulatory process, the recommendations are advisory only and any changes would still require FDA action through a formal regulatory process.
Jesse Dresser discusses the regulatory implications if the FDA ultimately adopts the committee’s recommendations. Jesse explains that adding eligible peptides to the FDA’s 503A Bulks List would establish a legal pathway for licensed compounding pharmacies to prepare those products pursuant to valid patient-specific prescriptions, while emphasizing that the committee’s vote does not itself change the current legal landscape.
As the FDA considers its next steps, the outcome could have significant implications for compounding pharmacies, healthcare providers, telehealth companies, and others operating in the peptide space. Until the agency completes its review and any subsequent rulemaking, the current regulatory framework remains in place, making continued attention to FDA developments essential for industry stakeholders.
